

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

**Complete if Known**

Application Number	09/763,037
Filing Date	February 15, 2001
First Named Inventor	Ben M. Dunn
Group Art Unit	1646
Examiner Name	unknown
Attorney Docket Number	UF-219XC1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	U1					
	U2					
	U3					
	U4					
	U5					
	U6					
	U7					
	U8					
	U9					
	U10					
	U11					
	U12					
	U13					
	U14					

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
cm	F1		DE 197 03 131	A1	Bayer AG	07-30-1998	All	
	F2		WO 97/03055	A1	Prochaska	01-30-1997	All	
	F3		WO 96/22778	A1	Schinazi <i>et al.</i>	08-01-1996	All	
	F4		WO 97/49411	A1	St. Clair <i>et al.</i>	12-31-1997	All	
	F5		WO 96/23509	A1	Chodakewitz <i>et al.</i>	08-08-1996	All	
	F6		WO 96/30025	A1	Barry <i>et al.</i>	10-03-1996	All	
	F7		WO 99/55372	A1	Currie <i>et al.</i>	11-04-1999	All	
	F8		WO 99/66936	A1	Schinazi <i>et al.</i>	12-29-1999	All	
	F9							
	F10							

Examiner  
Signature

cm

Date  
Considered

9-30-02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/763,037</td> </tr> <tr> <td>Filing Date</td> <td>February 15, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Ben M. Dunn</td> </tr> <tr> <td>Group Art Unit</td> <td>1646</td> </tr> <tr> <td>Examiner Name</td> <td>unknown</td> </tr> <tr> <td>Attorney Docket Number</td> <td>UF-219XC1</td> </tr> </table>		Application Number	09/763,037	Filing Date	February 15, 2001	First Named Inventor	Ben M. Dunn	Group Art Unit	1646	Examiner Name	unknown	Attorney Docket Number	UF-219XC1
Application Number	09/763,037														
Filing Date	February 15, 2001														
First Named Inventor	Ben M. Dunn														
Group Art Unit	1646														
Examiner Name	unknown														
Attorney Docket Number	UF-219XC1														
Sheet	2	of	4												

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BOUCHER, C. A. B. <i>et al.</i> "High-Level Resistance to (-) Enantiomeric 2' -Deoxy -3'- Thiacytidine In Vitro Is Due to One Amino Acid Substitution in the Catalytic Site of Human Immunodeficiency Virus Type 1 Reverse Transcriptase" <i>Antimicrobial Agents And Chemotherapy</i> , Oct. 1993, pp. 2231-2234, Vol. 37, No. 10.	
	R2	DEEKS, S. G. <i>et al.</i> "HIV-1 Protease Inhibitors" <i>JAMA</i> , January 8, 1997, pp. 145-153, Vol. 277, No. 2.	
	R3	DUNN, B. M. <i>et al.</i> "Subsite Preferences of Retroviral Proteinases" <i>Methods in Enzymology</i> , 1994, pp. 254-278, Vol. 241, Academic Press, Inc.	
	R4	GARDNER, M. B. "Simian and Feline Immunodeficiency Viruses: Animal Lentivirus Models for Evaluation of AIDS Vaccines and Antiviral Agents" <i>Antiviral Research</i> , 1991, pp. 267-286, Vol. 15, Elsevier Science Publishers B.V.	
	R5	HARRIGAN, R. "Measuring Viral Load in the Clinical Setting" <i>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> , 1995, pp. S34-S40, Vol. 10 (Suppl. 1), Lippincott-Raven Publishers, Philadelphia.	
	R6	HART, S. <i>et al.</i> "Long-Term Treatment of Diseased, FIV-Seropositive Field Cats with Azidothymidine (AZT)" <i>J. Vet. Med. A.</i> , 1995, pp. 397-409, Vol. 42, Blackwell Wissenschafts, Verlag, Berlin.	
	R7	HARTMANN, K. <i>et al.</i> "Use of Two Virustatica (AZT, PMEA) in the Treatment of FIV and of FeLV Seropositive Cats with Clinical Symptoms" <i>Veterinary Immunology and Immunopathology</i> , 1992, pp. 167-175, Vol. 35, Elsevier Science Publishers B.V., Amsterdam.	
	R8	HAYES, K. A. <i>et al.</i> "Prophylactic ZDV Therapy Prevents Early Viremia and Lymphocyte Decline But Not Primary Infection in Feline Immunodeficiency Virus-Inoculated Cats" <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1993, pp. 127-134, Vol. 6, Raven Press, Ltd., New York.	
	R9	HAYES, K. A. <i>et al.</i> "Early Suppression of Viremia by ZDV Does Not Alter the Spread of Feline Immunodeficiency Virus Infection in Cats" <i>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> , 1995, pp. 114-122, Vol. 9, No. 2, Raven Press. Ltd., New York.	
	R10	JOHNSON, C. M. <i>et al.</i> "FIV as a Model for AIDS Vaccination" <i>AIDS Research and Human Retroviruses</i> , 1994, pp. 225-228, Vol. 10, No. 3, Mary Ann Liebert, Inc., Publishers.	
	R11	KATLAMA, C. "Combination 3TC (Lamivudine)/ ZDV (Zidovudine) Vs. ZVD Monotherapy in ZVD Naïve HIV-1 Positive Patients With CD4 of 100-400 Cells/mm <sup>3</sup> , Abstr" <i>AIDS</i> , 1994, p. 56, Vol. 8 (Suppl. 4).	
	R12	LANGE, J. M. A. "Triple Combinations: Present and Future" <i>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> , 1995, pp. S77-S82, Vol. 10 (Suppl. 1), Lippincott-Raven Publishers, Philadelphia.	
	R13	LARDER, B. A. "Viral Resistance and the Selection of Antiretroviral Combinations" <i>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> , 1995, pp. S28-S33, Vol. 10 (Suppl. 1), Lippincott-Raven Publishers, Philadelphia.	

Examiner Signature		Date Considered	9-3-02
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
Application Number		09/763,037	
Filing Date		February 15, 2001	
First Named Inventor		Ben M. Dunn	
Group Art Unit		1646	
Examiner Name		unknown	
Attorney Docket Number		UF-219XC1	

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
cm	R14	MAGNANI, M. <i>et al.</i> "Feline Immunodeficiency Virus Infection of Macrophages: <i>In Vitro</i> and <i>in Vivo</i> Inhibition by Dideoxycytidine-5'- triphosphate-Loaded Erythrocytes" <i>AIDS Research and Human Retroviruses</i> , 1994, pp. 1179-1186, Vol. 10, No. 9, Mary Ann Liebert, Inc., Publishers.	
	R15	MEERS, J. <i>et al.</i> "Feline Immunodeficiency Virus Infection: Plasma, but not Peripheral Blood Mononuclear Cell Virus Titer is Influenced by Zidovudine and Cyclosporine" <i>Arch Virol</i> , 1993, pp. 67-81, Vol. 132.	
	R16	NEWELL, M. L. <i>et al.</i> "A Risk-Benefit Assessment of Zidovudine in the Prevention of Perinatal HIV Transmission" <i>Drug Safety</i> , 1995, pp. 274-281, Vol. 12, No. 4.	
	R17	NORTH, T. W. <i>et al.</i> "Feline Immunodeficiency Virus, a Model for Reverse Transcriptase-Targeted Chemotherapy for Acquired Immune Deficiency Syndrome" <i>Antimicrobial Agents and Chemotherapy</i> , June 1989, pp. 915-919, Vol. 33, No. 6, American Society for Microbiology.	
	R18	PAUL, D. B. <i>et al.</i> "Short-Term Stability of HIV Provirus Levels in the Peripheral Blood of HIV-Infected Individuals" <i>Journal of Medical Virology</i> , 1995, pp. 292-297, Vol. 47, Wiley-Liss, Inc.	
	R19	PEDERSEN, N. C. <i>et al.</i> "Isolation of a T-Lymphotropic Virus from Domestic Cats with an Immunodeficiency-Like Syndrome" <i>Science</i> , 1987, pp. 790-793, Vol. 235.	
	R20	PHILPOTT, M. S. <i>et al.</i> "Evaluation of 9-(2-Phosphonylmethoxyethyl) Adenine Therapy for Feline Immunodeficiency Virus Using a Quantitative Polymerase Chain Reaction" <i>Veterinary Immunology and Immunopathology</i> , 1992, p. 155-166, Vol. 35, Elsevier Science Publishers B. V., Amsterdam.	
	R21	SIEBELINK, K. H.J. <i>et al.</i> "Feline Immunodeficiency Virus (FIV) Infection in the Cat as a Model for HIV Infection in Man: FIV-Induced Impairment of Immune Function" <i>AIDS Research and Human Retroviruses</i> , 1990, pp. 1373-1378, Vol. 6, No. 12, Mary Ann Liebert, Inc., Publishers.	
	R22	SMITH, R. A. <i>et al.</i> "A Novel Point Mutation at Position 156 of Reverse Transcriptase from Feline Immunodeficiency Virus Confers Resistance to the Combination of (-)-β-2',3'-Dideoxy-3'-Thiacytidine and 3'-Azido-3'-Deoxythymidine" <i>Journal of Virology</i> , 1998, pp. 2335-2340, Vol. 72, No. 3.	
	R23	SMITH, R. A. <i>et al.</i> "A Novel Met-to-Thr Mutation in the YMDD Motif of Reverse Transcriptase from Feline Immunodeficiency Virus Confers Resistance to Oxathiolane Nucleosides" <i>Journal of Virology</i> , 1997, pp. 2357-2362, Vol. 71, No. 3.	
	R24	SMYTH, N. R. <i>et al.</i> "Susceptibility in Cell Culture of Feline Immunodeficiency Virus to Eighteen Antiviral Agents" <i>Journal of Antimicrobial Chemotherapy</i> , 1994, pp. 589-594, Vol. 34.	
	R25	SMYTH, N. R. <i>et al.</i> "Effect of 3'-Azido-2',3'-Deoxythymidine (AZT) on Experimental Feline Immunodeficiency Virus Infection in Domestic Cats" <i>Research in Veterinary Science</i> , 1994, pp. 220-224, Vol. 57.	
	R26	TISDALE, M. <i>et al.</i> "Rapid <i>in Vitro</i> Selection of Human Immunodeficiency Virus Type 1 Resistant to 3'-Thiacytidine Inhibitors Due to a Mutation in the YMDD Region of Reverse Transcriptase" <i>Proc. Natl. Acad. Sci. USA</i> , June 1993, pp. 5653-5656, Vol. 90.	

Examiner Signature	cm	Date Considered	9-30-02
--------------------	----	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	09/763,037
Filing Date	February 15, 2001
First Named Inventor	Ben M. Dunn
Group Art Unit	1646
Examiner Name	unknown
Attorney Docket Number	UF-219XC1

Sheet 4 of 4

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Cm	R27	TORRES, R. A. <i>et al.</i> "Combination Antiretroviral Therapy for HIV Infection" <i>Infect. Med.</i> , February 1997, pp. 142-160, Vol. 14.	
	R28	WLODAWER, A. <i>et al.</i> "Structure of an Inhibitor Complex of the Proteinase From Feline Immunodeficiency Virus" <i>Nature Structural Biology</i> , June 1995, pp. 480-488, Vol. 2, No. 6.	
	R29	YAMAMOTO, J. <i>et al.</i> "Pathogenesis of Experimentally Induced Feline Immunodeficiency Virus Infection in Cats" <i>Am J Vet Res</i> , August 1988, pp. 1246-1258, Vol. 49, No. 8.	
	R30	YAMAMOTO, J. <i>et al.</i> "Feline Immunodeficiency Syndrome--A Comparison Between Feline T-Lymphotropic Lentivirus and Feline Leukemia Virus" <i>Leukemia</i> , December 1988, pp. 204S-215S, Vol. 2, No. 12 Supplement.	
	R31		
	R32		
	R33		
	R34		
	R35		
	R36		
	R37		
	R38		
	R39		

Examiner  
Signature

Cm

Date  
Considered.

9/30/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

h:\doc\pto\IDS\UF-219XC1.form\sl